Display options
Cite
Ji R, Li Y, He C, et al. Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation. Gland Surg. 2020;9(6):2175-2186doi: 10.21037/gs-20-811.
Ji, R., Li, Y., He, C., Zhu, X., He, A., & Lu, Y. (2020). Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation. Gland surgery, 9(6), 2175-2186. https://doi.org/10.21037/gs-20-811
Ji, Rui, et al. "Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation." Gland surgery vol. 9,6 (2020): 2175-2186. doi: https://doi.org/10.21037/gs-20-811
Ji R, Li Y, He C, Zhu X, He A, Lu Y. Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation. Gland Surg. 2020 Dec;9(6):2175-2186. doi: 10.21037/gs-20-811. PMID: 33447568; PMCID: PMC7804549.
Copy Download .nbib Format: NLM
Share it on

Gland Surg. 2020 Dec;9(6):2175-2186. doi: 10.21037/gs-20-811.

Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.

Gland surgery

Rui Ji, Yong Li, Chenyun He, Xinghua Zhu, Aiqin He, Yunyan Lu

Affiliations

  1. Department of Gynecology, Affiliated Cancer Hospital of Nantong University, Nantong, China.
  2. Department of Pathology, Affiliated Cancer Hospital of Nantong University, Nantong, China.

PMID: 33447568 PMCID: PMC7804549 DOI: 10.21037/gs-20-811

Abstract

BACKGROUND: The purpose of this study was to explore the clinical significance of CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp in ovarian cancer.

METHODS: Ovarian cancer patients were recruited from Nantong Cancer Hospital between March 2006 and July 2011. The expressions of CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp were determined by immunohistochemistry (IHC).The chi-square test (χ

RESULTS: The results of IHC showed that the positive expression rates of CA125, CK7, ER, C-erbb2, and P-gp in malignant ovarian cancer tissues were significantly higher than those in benign ovarian cancer tissues. CA125 expression in malignant ovarian cancer was significantly correlated with the age of patients and the Federation of International Gynecology and Obstetrics (FIGO) stage. CK7 expression in malignant ovarian cancer was significantly correlated with the age, tissue differentiation, and number of residual lesions. CK20 expression in malignant ovarian cancer was significantly correlated with the age and tissue differentiation of the patients. ER expression in malignant ovarian cancer was significantly correlated with the age of patients and FIGO stage. PR expression in malignant ovarian cancer was significantly correlated with the age of the patients. C-erbb2 expression in malignant ovarian cancer was significantly correlated with the age of the patients. P-gp expression in malignant ovarian cancer was significantly correlated with the patient age, pathological type, and tissue differentiation. The expression of CA125, CK7, CK20, C-erbb2, and P-gp had significant effects on the prognosis of patients with ovarian cancer. The COX regression analysis showed that

CONCLUSIONS: In malignant ovarian cancer tissues, CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp are over-expressed. The expression of P-gp is an independent risk factor for ovarian cancer, and it can be an important target for the treatment of malignant ovarian cancer.

2020 Gland Surgery. All rights reserved.

Keywords: C-erbb2; CA125; CK20; CK7; COX; Kaplan-Meier; Ovarian cancer; P-gp; estrogen receptor (ER); progesterone receptor (PR)

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs-20-811). The authors have no conflicts of interest to declare.

References

  1. Gynecol Oncol. 1998 Aug;70(2):176-82 - PubMed
  2. Cancer Lett. 2001 Aug 28;169(2):155-64 - PubMed
  3. Hum Pathol. 2002 Nov;33(11):1078-85 - PubMed
  4. Int J Gynecol Pathol. 1983;2(3):275-85 - PubMed
  5. Chin Clin Oncol. 2018 Dec;7(6):56 - PubMed
  6. CA Cancer J Clin. 2017 Jan;67(1):7-30 - PubMed
  7. Mol Med Rep. 2018 Dec;18(6):5327-5336 - PubMed
  8. Int J Gynecol Cancer. 2012 May;22 Suppl 1:S5-8 - PubMed
  9. Am J Clin Pathol. 2002 Jun;117(6):944-51 - PubMed
  10. Pathol Int. 2009 May;59(5):300-5 - PubMed
  11. Mod Pathol. 2000 Sep;13(9):962-72 - PubMed
  12. Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):127-31 - PubMed
  13. Cancer Res. 2001 Sep 15;61(18):6768-76 - PubMed
  14. Histopathology. 2005 Sep;47(3):231-47 - PubMed
  15. Blood. 1991 Sep 15;78(6):1413-9 - PubMed
  16. Exp Biol Med (Maywood). 2003 Mar;228(3):308-14 - PubMed
  17. Cancer Lett. 1996 Apr 19;102(1-2):7-16 - PubMed
  18. Oncol Rep. 2007 Nov;18(5):1051-9 - PubMed
  19. CA Cancer J Clin. 2018 Nov;68(6):425-445 - PubMed
  20. J Korean Med Sci. 2004 Dec;19(6):826-33 - PubMed
  21. J Gynecol Oncol. 2013 Apr;24(2):167-76 - PubMed
  22. Cancer. 1995 Apr 15;75(8):2147-52 - PubMed
  23. Gynecol Oncol. 2011 Jun 1;121(3):429-30 - PubMed
  24. Nature. 2001 May 17;411(6835):355-65 - PubMed
  25. Clin Cancer Res. 1998 Sep;4(9):2245-51 - PubMed
  26. CA Cancer J Clin. 2019 Jan;69(1):7-34 - PubMed
  27. N Engl J Med. 1983 Oct 13;309(15):883-7 - PubMed
  28. Am J Surg Pathol. 2012 May;36(5):737-43 - PubMed
  29. Cancer. 2000 Oct 15;89(8):1783-91 - PubMed
  30. Gynecol Oncol. 2001 Jul;82(1):40-8 - PubMed
  31. Histopathology. 2019 Feb;74(3):452-462 - PubMed
  32. Cancer Res. 1989 Nov 1;49(21):6149-52 - PubMed
  33. Eur J Cancer. 2000 Dec;36(18):2411-9 - PubMed
  34. Gene. 1999 Oct 1;238(2):375-85 - PubMed
  35. J Clin Oncol. 2010 May 1;28(13):2128-30 - PubMed
  36. Plant Cell. 2002 Nov;14(11):2941-55 - PubMed
  37. Cancer Detect Prev. 1992;16(1):73-9 - PubMed
  38. J Natl Cancer Inst. 1986 Dec;77(6):1197-202 - PubMed
  39. Reprod Biol Endocrinol. 2003 Oct 07;1:73 - PubMed
  40. Int J Gynecol Pathol. 2002 Oct;21(4):391-400 - PubMed
  41. Br J Cancer. 2002 Jul 29;87(3):251-7 - PubMed
  42. Am J Clin Pathol. 1999 Mar;111(3):311-6 - PubMed

Publication Types